Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Payables (2016 - 2025)

Historic Payables for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $303.1 million.

  • Ptc Therapeutics' Payables fell 987.23% to $303.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $303.1 million, marking a year-over-year decrease of 987.23%. This contributed to the annual value of $304.3 million for FY2024, which is 2237.11% down from last year.
  • Ptc Therapeutics' Payables amounted to $303.1 million in Q3 2025, which was down 987.23% from $338.9 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Payables high stood at $392.0 million for Q4 2023, and its period low was $205.6 million during Q1 2021.
  • In the last 5 years, Ptc Therapeutics' Payables had a median value of $329.3 million in 2022 and averaged $312.3 million.
  • Per our database at Business Quant, Ptc Therapeutics' Payables surged by 4352.52% in 2021 and then crashed by 2237.11% in 2024.
  • Ptc Therapeutics' Payables (Quarter) stood at $288.8 million in 2021, then rose by 10.94% to $320.4 million in 2022, then increased by 22.35% to $392.0 million in 2023, then fell by 22.37% to $304.3 million in 2024, then fell by 0.38% to $303.1 million in 2025.
  • Its last three reported values are $303.1 million in Q3 2025, $338.9 million for Q2 2025, and $317.8 million during Q1 2025.